4//SEC Filing
Cohen Neil Harris 4
Accession 0001178913-22-001117
CIK 0001534248other
Filed
Mar 14, 8:00 PM ET
Accepted
Mar 15, 4:07 PM ET
Size
16.0 KB
Accession
0001178913-22-001117
Insider Transaction Report
Form 4
Cohen Neil Harris
Directorinterim CEO
Transactions
- Purchase
American Depositary Shares
2022-03-14$4.20/sh+2,000$8,400→ 6,409 total - Purchase
American Depositary Shares
2022-03-14$4.30/sh+2,000$8,600→ 8,409 total - Purchase
American Depositary Shares
2022-03-14$4.56/sh+2,000$9,120→ 10,409 total - Award
Option to Purchase American Depositary Shares
2022-03-07+6,820→ 6,820 totalExercise: $3.53Exp: 2032-03-07→ American Depositary Shares (6,820 underlying) - Award
Option to Purchase American Depositary Shares
2021-04-19+11,884→ 11,884 totalExercise: $27.26Exp: 2031-04-19→ American Depositary Shares (11,884 underlying) - Award
Option to Purchase American Depositary Shares
2021-03-16+688→ 688 totalExercise: $13.17Exp: 2030-07-15→ American Depositary Shares (688 underlying)
Footnotes (6)
- [F1]Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
- [F2]The ADSs are held of record directly by the Phoenix Insurance Company Ltd. (Naftali Neil Cohen) (the "IRA"), which is self-managed by the Reporting Person. The Reporting Person is the sole beneficiary of the IRA and may be deemed to have sole voting and dispositive power with respect to the ADSs held by IRA.
- [F3]No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
- [F4]These options vest and become exercisable in their entirety on March 16, 2023 subject to the Reporting Person's continued service.
- [F5]These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
- [F6]These options vest and become exercisable as follows: 1/3 vest on July 16, 2021, and the remaining options vest on a quarterly basis for the following eight quarters, subject to the Reporting Person's continued service.
Documents
Issuer
Chemomab Therapeutics Ltd.
CIK 0001534248
Entity typeother
Related Parties
1- filerCIK 0001840006
Filing Metadata
- Form type
- 4
- Filed
- Mar 14, 8:00 PM ET
- Accepted
- Mar 15, 4:07 PM ET
- Size
- 16.0 KB